Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, and Viacom, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.
WHY THIS MATTERS IN BRIEF
AI and blockchain are two incredibly powerful technologies, but for different reasons, however, when they’re combined their significance, and impact, becomes even greater.
The combination of Blockchain and Artificial Intelligence (AI) “could bring significant improvements to a healthcare sector plagued by interoperability problems and big data analytics shortfalls,” says IBM Watson Health Chief Science Officer Shahram Ebadollahi.
Speaking at an event recently Ebadollahi announced that IBM will be expanding its “exploration of healthcare related blockchain opportunities” with its newest partner the Center of Disease Control (CDC) who have already run a number of blockchain pilots, which were mainly centred around public health responses and crisis situations, and who are now looking to find new use cases for the technology.
The partnership will complement an existing collaboration between IBM Watson and the FDA, giving IBM additional insight into how blockchain, in tandem with AI, could overhaul the way stakeholders extract meaning from the overwhelming volume of big data in the industry.
“Blockchain is very useful when there are lots of actors in the system,” Ebadollahi said, “and it enables the ecosystem of data in healthcare to have more fluidity, meanwhile adding the AI layer allows us to extract new insights from trusted data.”
“Blockchain is a major focus area for IBM as a whole,” said Ebadollahi, “and it’s a big investment for IBM – and of course, Watson Health thinks blockchain could have a major impact in healthcare and life sciences, especially around how data is being stored, shared, and used for its various applications.”
Blockchain purports to offer enhanced security and data integrity, as well as opportunities for patients to maintain more control over who accesses their data and how it is shared.
“Healthcare data resides in many different places – the primary care provider, the hospital, or the lab where their results are processed – but if you have the patient’s consent to share the data, you can pull together these different elements for use within a particular application or service that they need,” he explained.
“A permissioned blockchain brings together trusted collaborators. Each of them can join the chain, or run their own chains, and the distributed ledger will keep track of all the events that are of importance for that particular iteration of providers within a patient’s care team for whatever task they’re trying to accomplish.”
Payers are also keenly interested in creating a more trustworthy data management system, which could better support “value based” care and the complex administrative processes that are currently involved in healthcare claims adjudication and payments.
“As risk-based reimbursement continues to exert influence over the payer-provider relationship, blockchain may also offer an innovative approach to measuring and rewarding performance,” adds Hashed Health CEO John Bass, “blockchain is one of the emerging technologies that would allow payers to programmatically throttle payments or incentives based on external data sources instead of adjusting payments through laborious administrative processes. As long as you can provide an attestation that a certain best practice is being followed, you can create credits and debits in the provider’s virtual wallet to provide incentives. That is a fundamental redesign of what value transfers look like today.”
Almost all of the US’s large health plans are currently implementing or actively planning to spin up a blockchain solution for at least some of their admin needs, and activity in the payer space is quickly outpacing interest on the provider side with 68 percent of all size payers aiming to take a blockchain approach to at least one business problem by the end of 2018, while just 12 percent of providers are planning to do the same.
As with financial services and banking though the payer use cases, such as using Blockchain to help improve the operational efficiency of back-end processes might be clearer at the moment, leading to speedier adoption rates.
Payers may then also be able to use AI tools to identify fraud or incorrect billings more efficiently if blockchain-based provider identity management and claims adjudication techniques make it easier to identify anomalies in billing patterns.
However, adding a layer of AI to this blockchain substrata could also drastically improve the way healthcare providers extract actionable insights from big data that is fundamentally more trustworthy than before.
If a patient himself has verified that his record is complete, up-to-date, and accurate on a permissioned blockchain, AI algorithms that stratify risk, suggest diagnoses, or identify gaps in care might also be more efficient and effective, for example.
A recent Frost & Sullivan report suggests that the convergence of blockchain with machine learning and AI could also reduce pharmaceutical supply chain issues, create better clinical trials, and allow the integration of Internet of Things (IoT) data into the clinical care environment.
“A blockchain-based system will enable unprecedented collaboration, bolstering innovation in medical research and the execution of larger healthcare concepts such as precision medicine and population health management,” said Transformational Health industry analyst Kamaljit Behera, “blockchain technology may not be the panacea for healthcare industry challenges needs but it holds the potential to save billions of dollars by optimizing current workflows and disintermediating some high-cost gatekeepers.”
The confluence of blockchain and AI is not too far away either, Behara noted. By 2025, Frost & Sullivan expects the healthcare industry to be deeply immersed in both technologies across the payer, provider, and pharmaceutical segments.
IBM also believes the inflection point for AI and blockchain is just over the horizon. While the industry is still in its infancy at the moment, progress happens quickly, and unforeseen breakthroughs can radically alter the technology experience in just a few short years.
“When a bunch of physicists collaborated and created this thing called the World Wide Web a few decades ago, nobody imagined Facebook and Google and Amazon,” said Ebadollahi, “with blockchain we can collect data and extract insights through AI, and the future will have an economy around that we can hardly even imagine right now.”